MGMT

You have access
Association of MGMT Gene Promoter Methylation With Clinicopathological Parameters in Patients With Wild-type IDH Glioblastoma
MOONSIK KIM, JIHWAN YOO, JONG HEE CHANG and SE HOON KIM

Anticancer Research January 2022, 42 (1) 335-341; DOI: https://doi.org/10.21873/anticanres.15490
You have access
Probing the Oncolytic and Chemosensitizing Effects of Dihydrotanshinone in an In Vitro Glioblastoma Model
VARUN KUMAR, DANIEL RADIN and DONNA LEONARDI

Anticancer Research November 2017, 37 (11) 6025-6030;
You have access
Analysis of Association Between MGMT and p53 Gene Single Nucleotide Polymorphisms and Laryngeal Cancer
YAYUN LV, CHUANLIANG JIA, AIHUA JIANG, HUA ZHANG, YUNQIANG WANG, FEIFEI LIU, LINLIN YANG, YAN SUN, RUNLI LV and XICHENG SONG

Anticancer Research August 2017, 37 (8) 4399-4403;
You have access
Impact of Therapy Sequence with Alkylating Agents and MGMT Status in Patients with Advanced Neuroendocrine Tumors
SEBASTIAN KRUG, MICHAEL BOCH, PETER REXIN, THOMAS M. GRESS, PATRICK MICHL and ANJA RINKE

Anticancer Research May 2017, 37 (5) 2491-2500;
You have access
Predictive Biomarkers to Chemotherapy in Patients with Advanced Melanoma Receiving the Combination of Cisplatin - Vinblastine - Temozolomide (PVT) as First-line Treatment: A Study of the Hellenic Cooperative Oncology Group (HECOG)
HELENA LINARDOU, GEORGE PENTHEROUDAKIS, IOANNIS VARTHALITIS, HELEN GOGAS, DIMITRIOS PECTASIDES, THOMAS MAKATSORIS, GEORGE FOUNTZILAS, DIMITRIOS BAFALOUKOS and The Hellenic Cooperative Oncology Group

Anticancer Research February 2015, 35 (2) 1105-1113;

Main menu

User menu

Search

MGMT